Company Profile

Hangzhou Jiuyuan Gene Engineering Co., Ltd.（2566.HK） is a high-tech enterprise specializing in the R&D, production and sales of biological drugs and medical devices. We focus on four rapidly growing therapeutic areas: orthopedics, metabolic diseases,oncology and hematology.The company was established in December 1993 and is one of the earliest genetic engineering pharmaceutical companies in Zhejiang Province and even in the whole country.

The company always upholds the concept “Taking gene engineering as orientation, Rendering service to human health”, to pursue innovation and to strive for excellence. In October 1996, the company took the lead in successful development and industrialization of a leukocyte promotion medicine named JILIFEN (Filgrastim, rhG-CSF), entered the market monopolized by U.S and Japanese manufacturers. Over the twenty years,the company has gradually developed a series of products including JILIFEN, JIPAILIN, JIJUFEN, YINUOJIA, JIOUTING, GUYOUDAO, JIFUWEI and JITANSU. Innovative implantable drug-device combination GUYOUDAO is the first rhBMP-2 containing bone repair material approved for sale in China,  and the product under development, JY29-2, is potentially the first Semaglutide biosimilar to be approved for commercialisation in China.At present, the company has a total of more than 1,500 employees, sales of more than 1.2 billion yuan in 2023, has been achieving  more than one billions revenues for consecutive several years.

Jiuyuan Gene is one of the first high-tech enterprises, and has won honorary titles such as National Torch Program Key High-tech Enterprise, National Intellectual Property Advantage Enterprise and Zhejiang Intellectual Property Demonstration Company. The company has multiple innovation platforms above the provincial level, including National postdoctoral workstation, Academician workstation,  Zhejiang Key Enterprise Research Institute (newly recognized in 2022), Zhejiang High-tech R&D Center, Zhejiang Enterprise Technology Center, and Zhejiang Key Innovation Team. The company has twice been named one of the "Top Ten High-tech Enterprises" in Hangzhou.

The company's R&D center currently has more than 110 empolyees, of which more than 60% are masters and doctors. The core researchers come from well-known domestic universities such as Peking University, Zhejiang University, Nanjing University, and China Pharmaceutical University. The research team has rich experience in project establishment, new drug discovery, pilot development, intellectual property rights, and clinical research. We have participated in many national or provincial research projects, have undertaken three major national science and technology projects, and have won a total of 11 national honors for our marketed products. After 30 years of R&D efforts, we have established six product development platforms, which enable us to continuously develop and advance pipeline products.

Gathering resources from all over the world, Jiuyuan strives to build a leading domestic biopharmaceutical company led by innovation and supported by the market.